Aclarion, Inc., (ACON): Price and Financial Metrics
ACON Price/Volume Stats
|Current price||$0.22||52-week high||$2.37|
|Prev. close||$0.23||52-week low||$0.21|
|Day high||$0.24||Avg. volume||744,702|
|50-day MA||$0.36||Dividend yield||N/A|
|200-day MA||$0.61||Market Cap||1.93M|
ACON Stock Price Chart Interactive Chart >
ACON Stock Summary
- ACON has a higher market value than just 0.93% of US stocks; more precisely, its current market capitalization is $2,374,113.
- ACLARION INC's stock had its IPO on April 22, 2022, making it an older stock than only 1.32% of US equities in our set.
- With a year-over-year growth in debt of 512.21%, ACLARION INC's debt growth rate surpasses 97.92% of about US stocks.
- If you're looking for stocks that are quantitatively similar to ACLARION INC, a group of peers worth examining would be RCEL, FARO, LUCD, OFIX, and CETX.
- To check out ACLARION INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001635077.
ACON Valuation Summary
- In comparison to the median Healthcare stock, ACON's price/earnings ratio is 101.88% lower, now standing at -0.5.
- Over the past 19 months, ACON's EV/EBIT ratio has gone up 4.
Below are key valuation metrics over time for ACON.
Aclarion, Inc., (ACON) Company Bio
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
ACON Latest News Stream
|Loading, please wait...|
ACON Latest Social Stream
View Full ACON Social Stream
Latest ACON News From Around the Web
Below are the latest news stories about ACLARION INC that investors may wish to consider to help them evaluate ACON as an investment opportunity.
Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel of 10 Key Opinion Leader (KOL) surgeons All commercial Nociscans to date have been completed on Siemens MRI scanners with additional acceleration of volumes expected as Philips scanners are onboarded BROOMFIELD, CO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or th
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care. Aclarion’s KOL panel represents spine surgeons at some of the largest and most influential academic centers and private practices in the country, including leaders of national societies that advocate for protocols to improve clinical treatments. The Company intends to activate MRIs for each KOL sur
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian Och Spine. Dr. Hartl becomes Aclarion’s 2nd KOL to get access to an MRI center authorized to perform Nociscans, adding NYC to Denver as the second active KOL site. Aclarion will report on Nociscan volumes to date before the end of the year and add this key metric to quarterly reporting beginning in
The Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, is funding ground-breaking low back pain research. The Back Pain Consortium (BACPAC) Research Program, a recipient of the NIH HEAL Initiative, is an effort to address the need for effective and personalized therapies for chronic low back pain (cLBP). Two BACPAC trials utilizing Aclarion’s Nociscan platform include the Biomarkers for Evaluating Spine Treatments (BEST) clinical trial and the comeBACK clinical study. BROOM
ACON Price Returns